Title: Implantable Bone-Conduction and Bone-Anchored Hearing Aids

Population

<table>
<thead>
<tr>
<th>Individuals:</th>
<th>Interventions</th>
<th>Comparators</th>
<th>Outcomes</th>
</tr>
</thead>
<tbody>
<tr>
<td>With conductive or mixed hearing loss</td>
<td>Implantable bone-anchored hearing aid with a percutaneous abutment</td>
<td>External hearing aid</td>
<td>Functional outcomes, Quality of life, Treatment-related morbidity</td>
</tr>
<tr>
<td>With conductive or mixed hearing loss</td>
<td>Partially implantable bone-anchored hearing aid with transcutaneous coupling to sound processor</td>
<td>External hearing aid</td>
<td>Functional outcomes, Quality of life, Treatment-related morbidity</td>
</tr>
<tr>
<td>With unilateral sensorineural hearing loss</td>
<td>Fully or partially implantable bone-anchored hearing aid and contralateral routing of signal</td>
<td>Air-conduction hearing aid with contralateral routing of signal</td>
<td>Functional outcomes, Quality of life, Treatment-related morbidity</td>
</tr>
</tbody>
</table>

State and Federal mandates and health plan member contract language, including specific provisions/exclusions, take precedence over Medical Policy and must be considered first in determining eligibility for coverage. To verify a member’s benefits, contact Blue Cross and Blue Shield of Kansas Customer Service.

The BCBSKS Medical Policies contained herein are for informational purposes and apply only to members who have health insurance through BCBSKS or who are covered by a self-insured group plan administered by BCBSKS. Medical Policy for FEP members is subject to FEP medical policy which may differ from BCBSKS Medical Policy.

The medical policies do not constitute medical advice or medical care. Treating health care providers are independent contractors and are neither employees nor agents of Blue Cross and Blue Shield of Kansas and are solely responsible for diagnosis, treatment and medical advice.

If your patient is covered under a different Blue Cross and Blue Shield plan, please refer to the Medical Policies of that plan.
DESCRIPTION
Sensorineural, conductive, and mixed hearing loss may be treated with various devices, including conventional air-conduction (AC) or bone-conduction external hearing aids. AC hearing aids may not be suitable for patients with chronic middle ear and ear canal infections, atresia of the external canal, or an ear canal that cannot accommodate an ear mold. Bone-conduction hearing aids function by transmitting sound waves through the bone to the ossicles of the middle ear and may be useful for individuals with conductive hearing loss, or (if used with contralateral routing of signal), for unilateral sensorineural hearing loss. Implantable, bone-anchored hearing aids (BAHAs) that use a percutaneous or transcutaneous connection to a sound processor have been investigated as alternatives to conventional bone-conduction hearing aids for patients with conductive or mixed hearing loss or for patients with unilateral single-sided sensorineural hearing loss.

OBJECTIVE
The objective of this policy is to examine whether implantable bone-anchored hearing aids improve health outcomes for individuals with conductive, mixed, or sensorineural hearing loss.

BACKGROUND
Hearing Loss
Hearing loss is described as conductive, sensorineural, or mixed, and can be unilateral or bilateral. Normal hearing is the detection of sound at or below 20 dB (decibel). The American Speech-Language-Hearing Association (ASLHA) has defined the degree of hearing loss based on pure-tone average (PTA) detection thresholds as mild (20 to 40 dB), moderate (40 to 60 dB), severe (60 to 80 dB), and profound (>80 dB). PTA is calculated by averaging the hearing sensitivities (ie, the minimum volume that the patient hears) at multiple frequencies (perceived as pitch), typically within the range of 0.25 to 8 kHz.

Sound amplification through the use of an air-conduction (AC) hearing aid can provide benefit to patients with sensorineural or mixed hearing loss. Contralateral routing of signal (CROS) is a system in which a microphone on the affected side transmits a signal to an AC hearing aid on the normal or less affected side.

Bone-Conduction Hearing Devices
External bone-conduction hearing aids function by transmitting sound waves through the bone to the ossicles of the middle ear. The external devices must be closely applied to the temporal bone, with either a steel spring over the top of the head or with the use of a spring-loaded arm on a pair of spectacles. These devices may be associated with either pressure headaches or soreness.

A bone-anchored implant system combines a vibrational transducer coupled directly to the skull via a percutaneous abutment that permanently protrudes through the skin from a small titanium implant anchored in the temporal bone. The system is based on osseointegration through which living tissue integrates with titanium in the implant over
3 to 6 months, conducting amplified and processed sound via the skull bone directly to
the cochlea. The lack of intervening skin permits the transmission of vibrations at a lower
energy level than required for external bone-conduction hearing aids. Implantable bone-
conduction hearing systems are primarily indicated for people with conductive or mixed
sensorineural or conductive hearing loss. They may also be used with CROS as an
alternative to an AC hearing aid for individuals with unilateral sensorineural hearing loss.

Partially implantable magnetic bone-conduction hearing systems, also referred to as
transcutaneous bone-anchored systems, are an alternative to bone-conduction hearing
systems that connect to bone percutaneously via an abutment. With this magnetic
technique, acoustic transmission occurs transcutaneously via magnetic coupling of the
external sound processor and the internally implanted device components. The bone-
conduction hearing processor contains magnets that adhere externally to magnets
implanted in shallow bone beds with the bone-conduction hearing implant. Because the
processor adheres magnetically to the implant, there is no need for a percutaneous
abutment to physically connect the external and internal components. To facilitate
greater transmission of acoustics between magnets, skin thickness may be reduced to 4
to 5 mm over the implant when it is surgically placed.

REGULATORY STATUS
Six Baha® sound processors manufactured by Cochlear Americas (Englewood, CO) have
been cleared for marketing by the U.S. Food and Drug Administration (FDA) through the
510(k) process for use with the Baha auditory osseointegrated implant system:
- Baha® 5
- BAHA Cordelle II™
- BAHA Divino™
- BAHA Intenso™ (digital signal processing)
- BAHA BP100™
- BAHA 4 (upgraded from the BP100)

FDA cleared the BAHA system for use in children aged 5 years and older and adults for
the following indications:
- Patients who have conductive or mixed hearing loss and can still benefit from
  sound amplification
- Patients with bilaterally symmetric conductive or mixed hearing loss may be
  implanted bilaterally
- Patients with sensorineural deafness in 1 ear and normal hearing in the other (ie,
  single-sided deafness)
- Patients who are candidates for an air-conduction contralateral routing of signals
  (AC CROS) hearing aid but who cannot or will not wear an AC CROS device

Other implantable bone-conduction hearing systems that rely on an abutment and have
similar indications as the Cochlear Americas' Baha devices:
- OBC Bone Anchored Hearing Aid System (Oticon Medical, Kongebakken,
- Ponto Bone Anchored Hearing System (Oticon Medical). Cleared in September 2012. A next-generation Ponto Pro device can be used with either Oticon or Baha implants.

Two partially implantable magnetic bone conduction devices that have received 510(k) clearance from the FDA are:
- Otomag Bone Conduction Hearing System (Sophono, Boulder, CO; now Medtronic, Minneapolis, MN),
- Cochlear BAHA® 4 Attract System (Cochlear Americas, Centennial, CO)

The BoneBridge™ (MedEl, Innsbruck, Austria) is another partially implantable bone-conduction implant that is considered an active transcutaneous device. It has been cleared for marketing in Europe but has not received FDA approval for use in the United States.

The SoundBite™ Hearing System (Sonitus Medical, San Mateo, CA) is an intraoral bone-conducting hearing prosthesis that consists of a behind-the-ear microphone and an in-the-mouth hearing device and was cleared for marketing through FDA’s 510(k) clearance process in 2011 for similar indications as the BAHA. Sonitus Medical closed in 2015.

FDA product code (for bone-anchored hearing aid): LXB. FDA product code (for implanted bone-conduction hearing aid): MAH.

Baha sound processors can be used with the Baha® Softband™. With this application, there is no implantation surgery. The sound processor is attached to the head using a hard or soft headband. The amplified sound is transmitted transcutaneously to the bones of the skull for transmission to the cochlea. In 2002, the Baha® Softband™ was cleared for marketing by FDA for use in children younger than 5 years. Because this application has no implanted components, it is not addressed in this evidence review.
POlICY
A. Unilateral or bilateral fully or partially implantable bone-conduction (bone-anchored) hearing aid(s) may be considered medically necessary as an alternative to an air-conduction hearing aid in patients 5 years of age and older with conductive or mixed hearing loss who also meet at least one of the following medical criteria:

1. Congenital or surgically induced malformations (eg, atresia) of the external ear canal or middle ear; **OR**

2. Chronic external otitis or otitis media; **OR**

3. Tumors of the external canal and/or tympanic cavity; **OR**

4. Dermatitis of the external canal;

**AND**

B. Meet the following audiologic criteria:

1. A pure tone average bone-conduction threshold measured at 0.5, 1, 2, and 3 kHz of better than or equal to 65 dB, **AND**

2. For bilateral implantation, patients should meet the above audiologic criteria, and have a symmetrically conductive or mixed hearing loss as defined by a difference between left and right side bone-conduction threshold of less than 10 dB on average measured at 0.5, 1, 2, and 3 kHz, or less than 15 dB at individual frequencies, **AND**

3. Speech discrimination score greater than 60% in the indicated ear.

C. An implantable bone-conduction (bone-anchored) hearing aid may be considered medically necessary as an alternative to an air-conduction contralateral routing of signal hearing aid in patients 5 years of age and older with single-sided sensorineural deafness and normal hearing in the other ear. The pure tone average air conduction threshold of the normal ear should be better than or equal to 20 dB measured at 0.5, 1, 2, and 3 kHz.

D. Other uses of implantable bone-conduction (bone-anchored) hearing aids, including use in patients with bilateral sensorineural hearing loss, are considered experimental / investigational.

POLICY GUIDELINES
In patients being considered for implantable bone-conduction (bone-anchored) hearing aid(s), skull bone quality and thickness should be assessed for adequacy to ensure implant stability. Additionally, patients (or caregivers) must be able to perform proper
hygiene to prevent infection and ensure the stability of the implants and percutaneous abutments.

Please refer to the member’s contract benefits in effect at the time of service to determine coverage or non-coverage of these services as it applies to an individual member.

RATIONALE
This policy is updated regularly with searches of the MEDLINE database, most recently through December 20, 2016.

The evidence related to the use of implantable bone-conduction devices, also referred to as bone-anchored hearing aids (BAHAs), is characterized by observational studies that report pre- and postimplant hearing outcomes for patients treated with these devices. Many of these studies combine patients with different underlying disease states and indications. No randomized controlled trials (RCTs) have compared implantable bone-conduction hearing aids to other hearing augmentation devices or sham devices. However, given the objectively measured outcomes and the largely invariable natural history of hearing loss in individuals who would be eligible for an implantable bone-conduction device, a within-subjects comparison of hearing before and after device placement may be a reasonable study design. This evidence review will first describe efficacy of BAHAs as a group, which includes studies using both percutaneous and transcutaneous devices, although most devices used in the studies were percutaneous. Second, the review will describe studies that focus on transcutaneous devices. Following is a summary of key findings.

Overall Efficacy of BAHAs
Systematic Reviews and Meta-Analyses
Two systematic reviews by the Health Technology Assessment Program were published in 2011 on the use of BAHAs for bilateral hearing impairment.\textsuperscript{1,2} The quality of available studies on the use of BAHAs was weak. No studies with control groups were identified. Cohort pre-post studies and cross-sectional comparative studies demonstrated improvements in hearing with use of BAHAs over conventional bone-conduction hearing aids or unaided hearing. However, whether improvements in hearing with BAHAs were greater than with air-conduction (AC) hearing aids was uncertain. Additionally, bilateral use of BAHAs improved hearing outcomes in some patients over unilateral use, but that evidence, too, was uncertain. Implant loss ranged between 6.1% and 19.4%. Reviewers noted that hearing-specific quality of life (QOL) improved, but overall QOL did not differ.

Observational Studies
Since publication of the systematic reviews, a number of observational studies have evaluated specific aspects of Baha implantation or reported outcomes in specific populations. Several have suggested that newer generation BAHAs with fully digital signal processors improve hearing to a greater degree than older generation devices.\textsuperscript{3,4}

In 2014, Faroosh et al retrospectively compared BAHa placement with reconstruction of the external auditory canal for children and adolescents with congenital aural atresia or stenosis who were treated at a single institution from 1988 to 2011.\textsuperscript{5} Sixty-eight patients were included; 49 underwent external auditory canal reconstruction (EACR) and 19 received a BAHa. Groups
differed significantly in terms of age, presence of bilateral atresia, and presence of an associated syndrome. Audiologic data were available for 41 patients. At short-term (<6 months postsurgery) follow-up, the BAHA group (44.3 dB) had larger hearing gains on AC than the EACR group (20.0 dB; p<0.001); similarly, the BAHA group had larger hearing gains at long-term (>1 year postsurgery) follow-up (44.5 dB vs 15.3 dB; p<0.001). QOL scores and requirements for revision surgery did not differ significantly between the groups.

In 2011, Ramakrishnan et al retrospectively reviewed BAHAs and Softband-held conductive hearing aids in 109 children and young adults in a single center. The patient population was unique in that many had craniofacial or genetic syndromes and hearing loss (22/109). Criteria for selection of the implanted device or the Softband were not described, though authors noted an uneven distribution by age, sex, and syndromic comorbidity. Primary measures were the Glasgow Benefit Inventory or Listening Situation Questionnaire (parent version) administered at least 3 months after hearing aid intervention. Mean overall Glasgow Benefit Inventory scores were +29 (range, 11-72). Mean Listening Situation Questionnaire score was 17, which was less than a referral cutoff of 22. Based on mean scores, authors concluded that this population benefitted from BAHAs and Softband-held conductive hearing aids. Conclusions were affected by the heterogeneous patient population, lack of preintervention measures, and lack of a controlled comparator group. Other series describing outcomes for pediatric patients treated with bone-anchored devices have reported a benefit in hearing scores, including den Besten et al (2015) in 79 children ages 17 and under.

Older case series have reported patient-reported benefits and satisfaction after BAHA placement. Some have suggested that the BAHA improved hearing better than early bone-conducting devices and AC hearing aids and produced acceptable hearing outcomes in individuals unable to tolerate an AC hearing aid.

Section Summary: Overall Efficacy of BAHA Devices
The available studies on the use of BAHAs are observational pre-post designs without control groups and cross-sectional comparative studies. Although the study designs were generally weak, in general, use of BAHAs was associated with larger improvements in hearing than conventional nonimplanted bone-conduction hearing devices or unaided hearing. Given the objectively measured outcomes and the largely invariable natural history of hearing loss in individuals who would be eligible for an implantable bone-conduction device, the demonstrated improvements in hearing after device placement are likely attributable to the device.

Bilateral BAHA Devices in Conductive or Mixed Hearing Loss
A number of studies have demonstrated a consistent improvement in speech recognition in noise and in sound localization using bilateral devices for people with conductive (CHL) or mixed hearing loss.

Janssen et al (2012) conducted a systematic review to assess the outcomes of bilateral versus unilateral BAHA for individuals with bilateral permanent CHL. The literature search included studies in all languages published between 1977 and July 2011. Studies were selected if subjects of any age had permanent bilateral CHL and bilateral implanted BAHAs. Outcomes of interest were any subjective or objective audiologic measures, QOL indicators, or reports of adverse events. Eleven studies met inclusion criteria; all were observational. The studies included a total of 168 patients, 155 of whom had BAHAs and 146 of whom had bilateral devices. In most studies, comparisons between unilateral and bilateral BAHA were intrasubject. Heterogeneity of
the methodologies between studies precluded meta-analysis, therefore, a qualitative review was
performed. Results from 3 (of 11) studies were excluded from synthesis because their patients
had been included in multiple publications. Adverse events were not an outcome measure of any
of the studies. In general, bilateral BAHA provided additional objective and subjective benefit
compared with unilateral BAHA. For example, the improvement in tone thresholds associated
with bilateral BAHA ranged from 2 to 15 dB, the improvement in speech recognition patterns
ranged from 4 to 5.4 dB, and the improvement in the Word Recognition Score ranged from 1%
to 8%. These results were based on a limited number of small observational studies consisting of
heterogeneous patient groups that varied in age, severity of hearing loss, etiology of hearing
loss, and previous amplification experience.

Examples of individual studies include the following. In 2001, Bosman et al reported on 25
patients who were using bilateral devices.15 They found that both speech recognition in noise and
directional hearing improved with the second device. Priwin et al (2004) reported similar findings
in 12 patients with bilateral devices.16 A 2005 consensus statement concluded that bilateral
devices resulted in binaural hearing with improved directional hearing and improved speech-in-
noise scores in those with bilateral CHL and symmetric bone-conduction thresholds.17 A number
of other studies cited in the 2005 consensus statement found benefits similar to those noted by
Bosman and by Priwin.15,16 Positive outcomes continue to be reported: Dun et al (2010)18
identified improvements in the Glasgow Benefit Inventory in 23 children, while Ho et al (2009)19
reported the same benefit in 93 adults.

Section Summary: Bilateral BAHA Devices in Conductive or Mixed Hearing Loss
The evidence on bilateral versus unilateral BAHAs for individuals with CHL or mixed hearing loss
consists of small observational studies with heterogeneous participants. In general, bilateral
BAHAs seem to provide additional objective and subjective benefit compared with unilateral
BAHAs.

BAHA Devices for Unilateral Sensorineural Hearing Loss
In 2015, Peters et al reported results from a systematic review of studies comparing BAHA
devices with contralateral routing of signal (CROS) systems to hearing aids with CROS for single-
sided deafness (SSD).20 Six studies met eligibility criteria, including 1 RCT and 3 prospective and
2 retrospective case series, 5 of which were considered to have moderate-to-high directness of
evidence and low-to-moderate risk of bias. The 5 studies (n=91 patients) with low or moderate
risk of bias; they were noted to have significant heterogeneity in the populations included. For
speech perception in noise, there was no consistent improvement with aided hearing over
unaided hearing in all environments. All studies reported equal sound localization and QOL
outcomes for both hearing conditions.

Baguley et al (2006) reviewed the evidence for contralateral BAHAs in adults with acquired
unilateral sensorineural hearing loss.21 None of the 4 controlled trials reviewed showed a
significant improvement in auditory localization with the bone-anchored device. However, speech
discrimination in noise and subjective measures improved with these devices: the BAHAs resulted
in greater improvements than those obtained with the conventional AC CROS systems.

Since publication of the Peters systematic review, 2 prospective, interventional studies have
compared patient outcomes with transcutaneous BAHA devices to CROS hearing aids for SSD.
Leterme et al (2015) assessed 24 adults with SSD, 18 of whom were evaluated with trials of both
hearing aids with CROS and bone conduction–assisted hearing using the Baha Softband.22 Most
(72%) patients, after completing trials of both devices, preferred the BAHA device to hearing aids with CROS. Glasgow Benefit Inventory and Abbreviated Profile of Hearing Aid Benefit (APHAB) scores did not differ significantly between devices. Sixteen of the 18 subjects elected to undergo implantation of a percutaneous BAHA device. In general, hearing improvement with the Baha Softband trial correlated with hearing improvements following device implantation. Snapp et al (2017) reported a prospective single-center study of 27 patients with unilateral severe-profound sensorineural hearing loss who had either a CROS (n=13) or transcutaneous BAHA (n=14) device. Mean device use was 66 months for the BAHAs and 34 months for CROS devices. Both BAHA and CROS groups had significant improvement in speech-in-noise performance, but neither showed improvement in localization ability. There were no differences between the devices for subjective measures of posttreatment residual disability or satisfaction as measured by the Glasgow Hearing Aid Benefit Profile (GHABP).

Several centers have reported on findings from observational studies that evaluated the benefits of BAHAs for patients with unilateral SSD. Most were retrospective. Studies representative of this group are described next.

Zeitler et al (2012) reported on a retrospective case series of 180 patients with SSD and residual hearing in the implanted ear who underwent unilateral or bilateral BAHA placement at a U.S. university medical center. Significant improvement was reported in objective hearing measures (speech-in-noise and monosyllabic word tests) following BAHA implantation. Subjective benefits from BAHAs varied across patients based on results from the GHABP, but patients with residual hearing in the affected ear tended toward improved satisfaction with their device postoperatively.

Additional series from various countries, with sample sizes ranging from 9 to 145 patients, have reported on outcomes after implantation of BAHAs for SSD. In general, these studies have indicated improvements in patient-reported speech quality, speech perception in noise, and patient satisfaction.

**Section Summary: BAHA Devices for Unilateral Sensorineural Hearing Loss**

Single-arm case series with sample sizes ranging from 9 to 180 patients have generally reported some improvements in patient-reported outcomes after implantation of bone conduction devices, but no improvements in speech recognition or hearing localization. However, in studies with comparators, outcomes for patients with bone-anchored devices were similar to those for patients with hearing aids with CROS.

**BAHA Devices in Children Younger Than Age 5 Years**

The BAHA device has been investigated in children younger than 5 years in Europe. Reports have described experiences with preschool children or children with developmental issues that might interfere with device maintenance and skin integrity. A 2-stage procedure may be used in young children. In the first stage, the fixture is placed into the bone and allowed to fully osseointegrate. After 3 to 6 months, a second procedure is performed to connect the abutment through the skin to the fixture.

The largest series in children under 5 years we identified, described by Amonoo-Kuofi et al (2015), included 24 children identified from a single center’s prospectively maintained database. Most patients underwent a 2-stage surgical approach. Most (52%) patients received the implant for isolated microtia or Goldenhar syndrome (16%). Following implantation, 13 (54%) patients had grade 2 or 3 local reactions assessed on the Holgers Scale (redness, moistness, and/or
granulation tissue) and 7 (29%) had grade 4 local reactions on this scale (extensive soft-tissue reaction requiring removal of the abutment). QOL scores (Glasgow Children’s Benefit Inventory; scoring range, -100 to 100) were obtained in 18 subjects/parents, with a finale mean score change of +40 points. Audiologic testing indicated that the average performance of the device fell within the range of normal auditory perception in noisy and quiet environments.

Marsella et al (2012) reported on a single-center experience in Italy with pediatric BAHAs from the inception of their program in 1995 to December 2009.44 Forty-seven children (21 girls, 26 boys) were implanted; 7 were younger than 5 years. Functional gain was significantly better with BAHAs than with conventional nonimplanted bone-conduction hearing aids, and there was no significant difference in terms of functional outcomes between the 7 younger patients and the rest of the cohort. Based on these findings, study authors suggested that implantation of children at an age younger than 5 years can be conducted safely and effectively in such settings. Report conclusions were limited by the small number of very young children in the sample and the limited statistical power to detect a difference between younger and older children.

Davids et al (2007) provided BAHA devices to children younger than 5 years of age for auditory and speech-language development, and retrospectively compared surgical outcomes for a study group of 20 children younger than 5 years and a control group of 20 older children.35 Children with cortical bone thickness greater than 4 mm underwent a single-stage procedure. The interstage interval for children having 2-stage procedures was significantly longer in the study group to allow implantation in younger patients without increasing surgical or postoperative morbidity. Two traumatic fractures occurred in the study group versus 4 in the older children. Three younger children required skin site revision. All children were wearing their BAHA devices at the time of writing. McDermott et al (2008) reported on the role of BAHAs in children with Down syndrome in a retrospective case analysis and postal survey of complication rates and QOL outcomes for 15 children ages 2 to 15 years.36 All used their BAHA devices at a 14-month follow-up. No fixtures were lost; skin problems were encountered in 3 patients. All 15 patients had improved social and physical functioning, attributed to improved hearing.

Section Summary: BAHA Devices in Children Younger Than Age 5 Years
There are few data on use of BAHA devices in children younger than 5. Three case series with a total of fewer than 60 children younger than 5 years have reported improvements in QOL after implantation with BAHA devices. One comparative observational study, with 7 children younger than 5, reported significantly better improvement in functional gain with BAHAs than with conventional nonimplanted bone-conduction hearing aids in an analysis including all ages.

Safety and Adverse Events Related to BAHA Devices
In addition to the efficacy literature on the BAHA devices, studies have assessed complications with these devices.

Systematic Reviews
Verheij et al (2016) published a systematic review on complications of tissue preservation surgical techniques with percutaneous BAHA devices including 18 studies with 381 devices.37 The implantation techniques reported in the studies were as follows: punch method, 4 studies (81 implants); linear incision technique without soft tissue reduction, 13 studies (288 implants); and Weber technique, 1 study (12 implants). Indications for surgery were SSD (n=68), sensorineural hearing loss (n=4), mixed hearing loss (n=65), or CHL (n=66). The Holgers classification was used to grade soft tissue reactions (grade 0, no reaction; grade 2, red and moist tissue; grade 3,
granulation tissue; grade 4, removal of skin-penetrating implant necessary due to infection). The incidence of Holgers 3 was 2.5% with the punch technique, 5.9% with the linear incision technique, and 0% with the Weber technique. Holgers 4 was reported in 1 patient implanted with the linear incision technique.

In 2013, Kiringoda and Lustig reported on a meta-analysis of complications related to BAHA implants. Selected were 20 studies that evaluated complications in 2134 adult and pediatric patients who received a total of 2310 BAHA implants. The quality of available studies was considered poor and lacking in uniformity. Complications related to BAHA implants were mostly minor skin reactions: The incidence of Holgers Scale grade 2 to 4 skin reactions ranged from 2.4% to 38.1% in all studies. The incidence of failed osseointegration ranged from 0% to 18% in adult and mixed population studies and from 0% to 14.3% in pediatric population studies. The incidence of revision surgery ranged from 1.7% to 34.5% in adult and mixed population studies and from 0.0% to 44.4% in pediatric population studies. Implant loss ranged from 1.6% to 17.4% in adult and mixed population studies and from 0.0% to 25% in pediatric studies.

Observational Studies

In 2012, Dun et al assessed soft tissue reactions and implant stability of 1132 percutaneous titanium implants for bone-conduction devices in a retrospective survey of 970 patients undergoing implants between 1988 and 2007 at a university medical center in the Netherlands. Study investigators also examined device usage and compared different patient age groups (children, adults, elderly patients) over a 5-year follow-up period. Implant loss was 8%. In close to 96% of cases, there were no adverse soft tissue reactions. Significantly more soft tissue reactions and implant failures were observed in children than in adults and elderly patients (p<0.05). Implant survival rates were lower in patients with than without mental retardation (p=0.001).

In 2010, Hobson et al reviewed complications of 602 patients at a tertiary referral center over 24 years and compared their observed rates to those published in 16 previous studies. The overall observed complication rate of 23.9% (144/602) was similar to other published studies (weighted mean complication rate, 24.9%). The most common complications were soft tissue overgrowth, skin infection, and fixture dislodgement. The observed rate of surgical revision of 12.1% (73/602) was also similar to previously published rates (weighted mean, 12.7%). Top reasons for revision surgery were identical to observed complications. In 2011, Wallberg et al reported on the status of 150 implants placed between 1977 and 1986 at a mean follow-up of 9 years. Implants were lost in 41 (27%) patients. Reasons for implant loss were: removal (16 patients), osseointegration failure (17 patients), and direct trauma (8 patients). In the 132 patients with implant survival, BAHAs were still being used by 119 (90%) patients at the 9-year follow-up. For children, implant complications were even more frequent, as reported by Kraai et al (2011) in a follow-up evaluation of 27 implants placed in children ages 16 years or younger between 2002 and 2009. In this retrospective report, soft tissue reactions occurred in 24 (89%) patients; implant removal or surgical revision was required in 10 (37%) patients; 24 (89%) patients experienced soft tissue overgrowth and infection; and 7 (26%) patients experienced implant trauma. Chronic infection and overgrowth at the abutment prevented use of the implant in 3 (11%) patients.

In 2014, Allis et al conducted a prospective observational cohort study with a retrospective historical control to evaluate complication rates of skin overgrowth, infection, and the need for revision surgery associated with a BAHA implant with a longer (8.5-mm) abutment. Twenty-one subjects were treated with the 8.5-mm abutment implant from 2011 to 2012 and were compared
to 23 subjects treated with a 5.5-mm abutment implant from 2010 to 2011. Groups were generally similar at baseline, except that patients with the 8.5-mm abutment implant were older (62 years vs 48 years, p=0.012). Patients in the longer abutment group were less likely to experience infection (10% vs 43%; p=0.02), skin overgrowth (5% vs 41%; p=0.007), and need for revision (10% vs 45%; p=0.012), respectively.

Other observational cohort studies, ranging in size from 47 to 974 subjects, have reported safety and adverse events outcomes after BAHA placement.44-47 Across these studies, implant loss ranged from 4% to 18%.

Different surgical techniques for implanting BAHA devices and specific BAHA designs have yielded better safety outcomes. In a 2016 systematic review of 30 articles on the association between surgical technique and skin complications following BAHA implantation, the dermatome technique (vs a skin graft or linear technique) was linked to more frequent skin complications.48 Fontaine et al (2014) compared complication rates for 2 BAHA surgical implantation techniques among 32 patients treated from 2004 to 2011.49 Complications requiring surgical revision occurred in 20% of cases who had a skin flap implantation method (n=20) and in 38% of cases who had a full-thickness skin graft implantation method (n=21; p=0.31). Hultcrantz and Lanis (2014) reported shorter surgical times and fewer cases of numbness and peri-implant infections in 12 patients treated with a non-skin-thinning technique, compared with 24 patients treated with a flap or a dermatome implantation technique.50 In a comparison of 2 types of BAHA devices, one with a 4.5-mm diameter implant and a rounded 6-mm abutment (n=25) and one with a 3.75-mm diameter implant and a conically shaped 5.5-mm abutment (n=52), Nelissen et al (2014) reported that implant survival was high for both groups over a 3-year follow-up, although the conically shaped abutment had greater stability.51 Singam et al (2014) reported results of a BAHA implantation technique without soft tissue reduction in conjunction with a longer device abutment in 30 patients.52 Twenty-five patients had no postoperative complications. Five subjects developed postoperative skin reactions, of whom 3 required soft tissue reduction. Roplekar et al (2016) compared skin-related complications of the traditional skin flap method to the linear incision method performed by a single surgeon in 117 patients with at least 1 year of follow-up.53 Twenty-one (24%) patients experienced skin-related complications in the skin flap group (12 skin overgrowths, 8 wound infections, 1 numbness) and 3 (10%) patients experienced complications in the linear incision group (3 wound infections).

Section Summary: Safety and Adverse Events Related to BAHA Devices
The quality of available data for adverse events is generally poor with high heterogeneity. The most frequently reported complication from surgical procedures for BAHA insertion are adverse skin reactions, with an incidence of Holgers grade 2 to 4 reactions ranging from less than 2% to more than 34%, and implant loss ranging from less than 2% to more than 17%. There is some evidence of improvement in complication rates and severity with newer surgical techniques such as linear incision.

Partially Implantable Magnetic BAHA Devices
A smaller body of literature addresses outcomes associated with transcutaneous, partially implantable bone-anchored devices that magnetically couple the sound processor with the implant. Similar to the literature on percutaneous bone-anchored devices, most studies use a within-subjects comparison of hearing thresholds with and without the device. The indications for partially implantable systems are the same as those for transcutaneous bone-anchored devices.
Prospective Studies
Two prospective studies evaluating different transcutaneous systems were identified. Both trials were small (27 and 15 individuals), but both demonstrated improvements in hearing outcomes.

Briggs et al (2015) reported on a prospective interventional evaluation of the percutaneous, partially implantable Baha Attract System among 27 adults with a CHL or mild mixed hearing loss in the ear to be implanted. The choice of sound processor was based on patient preference and hearing tests with various sound processors in conjunction with Baha Softband prior to device implantation. All 27 patients enrolled received an implant. Sound processor fitting occurred 4 weeks postimplantation in all but 1 patient. At 9-month follow-up, pure-tone audiometry (PTA; means of 500, 1000, 2000, and 4000 Hz) was significantly improved with the implant and sound processor compared with unaided hearing (18.4-dB hearing loss; p<0.001). Patients generally showed improvements in speech recognition in noise, although comparing results across test sites was difficult due to different languages and methodologies used for testing speech recognition at each site. Compared with the preoperative unaided state, scores on the APHAB overall score (p=0.038) and reverberation (p=0.016) and background noise (p=0.035) subscales.

Denoyelle et al (2015) reported on a prospective trial of the Sophono device in children ages 5 to 18 years with uni- or bilateral congenital aural atresia with complete absence of the external auditory canal with pure CHL. The study included a within-subject comparison of hearing results with the Sophono devices to those obtained with the Baha Softband preoperatively. All 15 patients enrolled were implanted (median age, 97 months). At 6-month follow-up, mean aided AC PTA was 33.49 (mean gain, 35.53 dB), with a mean aided sound reception threshold of 38.2 (mean gain, 33.47 dB). The difference in AC PTA between the Baha Softband and the Sophono device was 0.6 dB (confidence interval upper limit, 4.42 dB), which met the study’s prespecified noninferiority margin. Adverse events were generally mild, including skin erythema in 2 patients, which improved by using a weaker magnet, and brief episodes of pain or tingling in 3 patients.

Nonrandomized Comparative Studies
A limited amount of data is available comparing transcutaneous to percutaneous bone-anchored conduction devices. In 2013, Hol et al compared percutaneous BAHA implants to partially implantable magnetic transcutaneous bone-conduction hearing implants using the Otomag Sophono device in 12 pediatric patients (age range, 5-12 years) who had congenital unilateral CHL. Sound-field thresholds, speech recognition threshold, and speech comprehension at 65 dB were somewhat better in patients with the BAHA implant (n=6) than in those with the partially implantable hearing device (n=6). Using a skull simulator, output was 10 to 15 dB lower with the partially implantable device than with the BAHA device. After following the same 12 patients for more than 3 years, Nelissen et al (2016) reported on soft tissue tolerability, hearing results, and sound localization abilities. Two patients in each group had stopped using their hearing devices. Soft tissue tolerability with the Sophono was favorable compared to BAHA. Both groups showed improvements in sound localization compared to the unaided situation. Aided thresholds with the Sophono were not as good as expected, with a mean pure-tone average of about 30 dB hearing loss; ideally aided thresholds should be 10 to 20 dB hearing loss.

Iseri et al (2015) described a retrospective, single-center study from Turkey comparing 21 patients treated with a transcutaneous, fully implantable BAHA to 16 patients treated with a percutaneous device (the Baha Attract). Groups were generally similar at baseline, with most individuals undergoing BAHA placement for chronic otitis media. Operating time was longer in patients treated with the transcutaneous partially implantable devices (46 minutes vs 26 minutes,
p<0.05). Three patients treated with percutaneous devices had Holgers Scale grade 2 skin reactions and 2 stopped using their devices for reasons unrelated to skin reactions. Mean thresholds for frequencies 0.5 to 4.0 kHz were 64.4 dB without the BAHA and 31.6 dB with the BAHA in the percutaneous device group, and 58.3 dB without the BAHA and 27.2 dB with the BAHA in the transcutaneous device group. Frequency-specific threshold hearing gains did not differ significantly between groups. Mean hearing gain measured by speech reception threshold was statistically significantly smaller in the percutaneous group (24 dB vs 36.7 dB, p=0.02).

Gerdes et al (2016) published a retrospective single-center study comparing 10 patients with CHL implanted with the transcutaneous Bonebridge device to an audiologically matched control group of 10 patients with the percutaneous BAHA BP100.59 There were similar significant improvements in aided thresholds, word recognition scores, and speech reception thresholds in noise for both devices. There were also no differences in subjective ratings for the APHAB scale. Mean functional gain was slightly higher (27.5 dB) for transcutaneous than for percutaneous (26.3 dB), but not significantly different.

**Observational Studies**

A moderately sized body of observational studies—most at a single center and with fewer than 10 patients—has reported outcomes for transcutaneous, partially implantable hearing systems. These studies are briefly described here to provide an overview of the functional gain and complications seen with the transcutaneously coupled devices.

Dimitriadis et al (2016) reported a systematic review of observational studies of the BAHA Attract device including 10 studies (total N=89 patients; range, 1-27 patients).60 Seventeen (19%) of the patients were children, of whom 5 had unilateral sensorineural hearing loss and 4 had CHL. Of the 27 (45%) adults, 22 had unilateral sensorineural hearing loss and 11 (18%) had bilateral mixed hearing loss. Audiologic and functional outcome measures and the timing of testing varied greatly in the studies. Summary measures were not reported. In general, audiologic and functional outcomes measured pre- and postimplantation showed improvement, although statistical comparisons were lacking in some studies.

Reddy-Kolanu et al (2016) reported on complications of the BAHA Attract (n=34) from a case series included all patients implanted in a single center between October 2013 and April 2015.61 Patients ranged in age from 8 to 64 years, and follow-up ranged from 3 to 20 months. Twenty-three patients had no significant postoperative problems. Five patients required an alteration in magnet strength primarily due to implant site tenderness. One patient reported distressing tinnitus; 1 had the implant changed to an abutment system due to infection; and 1 had the magnet removed following trauma to the implant site. One patient has ongoing psoriasis problems. Two patients were converted to a newer, lighter sound processor.

In an early (2011) study, Seigert reported on the use of a transcutaneous, partially implantable bone-conduction hearing system (Otomag).62 Among 12 patients who received the system, there were average hearing gains of 31.2 dB in free-field PTA. The free-field suprathreshold speech perception at 65 dB increased from 12.9% preimplantation to 72.1% postimplantation.

Powell et al (2015) reported outcomes from a retrospective study that included 6 patients treated with the Otomag Sophono device and 6 treated with the BAHA Attract device.63 Ten subjects were identified as the primary author’s patients and the remaining were identified through an Australian national hearing database. In the BAHA Attract group, mean AC thresholds across 4
frequencies (0.5, 1, 2, and 4 kHz) improved from 60.8 dB in the unaided state to 30.6 dB in the aided state. In the Sophono group, the mean 4-frequency AC thresholds improved from 57.8 dB in the unaided state to 29.8 dB in the aided state. Speech discrimination in noise scores did not differ significantly between devices.

O’Niel et al (2014) reported outcomes for 10 pediatric patients with CHL treated with the Otomag Sophono device at a single center.64 Fourteen ears were implanted with no surgical complications. The skin complication rate was 35.7%, including skin breakdown (n=2) and pain and erythema (n=5); negative outcomes resulted in 5 (36%) of 14 ears having sufficient difficulties to discontinue device use for a period. Mean aided PTA was a 20.2-dB hearing level, with a mean functional gain of a 39.9-dB hearing level. Patients without skin complications consistently used their devices (average daily use, 8-10 hours).

Centric et al (2014) also reported outcomes for 5 pediatric patients treated with the Otomag Sophono device at a single center.65 Etiologies of hearing loss were heterogeneous and included bilateral moderate or severe CHL and unilateral sensorineural hearing loss. Average improvement in PTA was a 32-dB hearing level, and the average improvement in speech response threshold was a 28-dB hearing level. All patients responded in the normal-to-mild hearing loss range in the implanted ear after device activation. In a follow-up study from the same institution, Baker et al (2015) reported pooled outcomes for the first 11 patients treated with the Otomag Sophono and the first 6 patients treated with the Baha Attract.66 Pre- and postimplant audiometric data were available for 11 ears in the Sophono group and 5 in the Baha Attract group. Average improvement over all frequencies ranged from a 24- to 43-dB hearing level in the Sophono group and from a 32- to 45-dB hearing level in the Baha Attract group. Average improvement in PTA was a 38-dB hearing level in the Sophono group and a 41-dB hearing level in the Baha Attract group.

Other single-center observational series have described clinical experience with transcutaneous partially implantable BAHA devices. Marsella et al (2014) reported outcomes for 6 pediatric patients treated with the Otomag Sophono device for CHL or mixed hearing loss.67 Median improvement in PTA was 33-dB hearing loss and median free-field PTA (0.5-3 kHz) with the device was 32.5-dB hearing loss. Magliulo et al (2015) reported outcomes for 10 patients treated with the Otomag Sophono device after subtotal petrosectomy for recurrent chronic middle ear disease, a procedure associated with a CHL of 50 to 60 dB.68 Postsurgery with the Sophono device, there was an average acoustic improvement in AC of 29.7 dB, which was significantly better than the improvement seen with traditional AC hearing aids (18.2 dB).

In addition to studies of partially implantable bone-conduction devices currently approved by the Food and Drug Administration, a number of case series identified evaluated the Bonebridge implant, which is not currently cleared for marketing in the United States. Case series with at least 5 patients are summarized in Table 1.

**Table 1: Case Series Evaluating the Bonebridge Implant**

<table>
<thead>
<tr>
<th>Study</th>
<th>N</th>
<th>Patient Population</th>
<th>Main Hearing Results</th>
<th>Safety Outcomes</th>
</tr>
</thead>
<tbody>
<tr>
<td>Schmerber et al</td>
<td>25</td>
<td>SSD (n=12) Bilateral CHL (n=7) Bilateral mixed HL (n=6)</td>
<td>SSD, in 5/7 patients speech reception threshold in noise lower with Bonebridge activated CHL and mixed, average functional gain: 26 dB HL; mean % of speech recognition in quiet improved from 74% unaided to 95% aided</td>
<td>No complications, device failures, revision surgery or skin injury reported with 1 y follow-up</td>
</tr>
</tbody>
</table>

## Study Summary: Partially Implantable Magnetic BAHA Devices

Studies of transcutaneous, partially implantable BAHAs have typically used a retrospective within-subjects comparison of hearing thresholds with and without the device, although there have been 2 small (27 and 15 participants) prospective studies. There was heterogeneity in the audiologic and functional outcome measures used in the studies and the timing of testing. Studies of partially implantable BAHAs have generally demonstrated within-subjects improvements in hearing.

### SUMMARY OF EVIDENCE

For individuals who have conductive or mixed hearing loss who receive an implantable bone-anchored hearing device with a percutaneous abutment or a partially implantable bone-anchored hearing device with transcutaneous coupling to the sound processor, the evidence includes observational studies that report pre-post differences in hearing parameters after treatment with bone-anchored hearing aids (BAHAs). Relevant outcomes are functional outcomes, quality of life, and treatment-related morbidity. No prospective trials were identified. Observational studies reporting on within-subjects changes in hearing have generally reported hearing improvements with the devices. Given the objectively measured outcomes and the largely invariable natural history of hearing loss in individuals who would be eligible for an implantable bone-conduction device, the demonstrated improvements in hearing after device placement can be attributed to the device. Studies of partially implantable bone-anchored devices have similarly demonstrated

<table>
<thead>
<tr>
<th>Study</th>
<th>N</th>
<th>Patient Population</th>
<th>Main Hearing Results</th>
<th>Safety Outcomes</th>
</tr>
</thead>
<tbody>
<tr>
<td>Rahne et al (2015)</td>
<td>11</td>
<td>SSD (n=6; 1 sensorineural, 3 mixed, 2 conductive)</td>
<td>Aided sound field threshold improvement: 33.4 dB</td>
<td>1 case of chronic fibrosing mastoiditis requiring mastoidectomy and antrotomy; no other complications</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Bilateral CHL (n=2)</td>
<td>WRS improved from mean of 10% unaided to 87.5% aided</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Bilateral mixed HL or mixed/sensorineural (n=3)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Laske et al (2015)</td>
<td>9</td>
<td>Adults with SSD and normal contralateral hearing</td>
<td>Speech discrimination signal-to-noise improvement for aided vs unaided condition, sound presented to aided ear: 1.7 dB</td>
<td>Not reported</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Positive improvements on quality-of-life questions</td>
<td></td>
</tr>
<tr>
<td>Riss et al (2014)</td>
<td>24</td>
<td>Combined HL (n=9)</td>
<td>Average functional gain: 28.8 dB</td>
<td>Not reported</td>
</tr>
<tr>
<td></td>
<td></td>
<td>EAC atresia (n=12)</td>
<td>Monosyllabic word scores at 65-dB sound pressure increased from 4.6-53.7 percentage points</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>SSD (n=3)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Manrique et al (2014)</td>
<td>5</td>
<td>Mixed HL (n=4)</td>
<td>PTA improvement: 35.62 dB (p=0.01)</td>
<td>No perioperative complications reported</td>
</tr>
<tr>
<td></td>
<td></td>
<td>SSD (n=1)</td>
<td>Disyllabic word discrimination improvement: 20% (p=0.016)</td>
<td></td>
</tr>
<tr>
<td>Iler et al (2014)</td>
<td>6</td>
<td>Mixed HL (n=4)</td>
<td>PTA functional gain (average, 0.5-4.0 kHz): 34.5 dB</td>
<td>Prolonged wound healing in 1 case</td>
</tr>
<tr>
<td></td>
<td></td>
<td>CHL (n=2)</td>
<td>Speech discrimination at 65 dB</td>
<td></td>
</tr>
<tr>
<td>Desmet et al (2014)</td>
<td>44</td>
<td>All unilaterally deaf adults</td>
<td>Statistically significant improvement on APHAB and SHHIA</td>
<td>Not reported</td>
</tr>
<tr>
<td>Iseri et al (2014)</td>
<td>12</td>
<td>CHL (n=9)</td>
<td>Speech reception threshold increase: 19 dB</td>
<td>Postoperative hematoma requiring aspiration in 1 case</td>
</tr>
<tr>
<td></td>
<td></td>
<td>“Primarily conductive hearing loss” (n=3)</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

APHAB: Abbreviated Profile of Hearing Aid Benefit; CHL: conductive hearing loss; EAC: external auditory canal; HL: hearing loss; PTA: pure-tone average; SHHIA: Short Hearing Handicap Inventory for Adults; SSD: single-sided deafness; WRS: Word Recognition Score.
within-subjects improvements in hearing. The single-arm studies have shown improvements in hearing in the device-aided state. No direct comparisons other than within-individual comparisons with external hearing aids were identified, but, for individuals unable to wear an external hearing aid, there may be few alternative treatments. The evidence is sufficient to determine qualitatively that the technology results in a meaningful improvement in the net health outcome.

For individuals who have unilateral sensorineural hearing loss who receive a fully or partially implantable bone-anchored hearing device with contralateral routing of signal, the evidence includes 1 randomized controlled trial (RCT), multiple prospective and retrospective case series, and a systematic review. Relevant outcomes are functional outcomes, quality of life, and treatment-related morbidity. Single-arm case series, with sample sizes ranging from 9 to 145 patients, generally have reported improvements in patient-reported speech quality, speech perception in noise, and satisfaction with bone conduction devices with contralateral routing of signal. However, a well-conducted systematic review of studies comparing bone-anchored devices to hearing aids with contralateral routing of signal found no evidence of improvement in speech recognition or hearing localization. The single RCT included in the systematic review was a pilot study enrolling only 10 patients and, therefore, does not provide definitive evidence. The evidence is insufficient to determine the effects of the technology on health outcomes.

CLINICAL INPUT FROM PHYSICIAN SPECIALTY SOCIETIES AND ACADEMIC MEDICAL CENTERS

While the various physician specialty societies and academic medical centers may collaborate with and make recommendations during this process, through the provision of appropriate reviewers, input received does not represent an endorsement or position statement by the physician specialty societies or academic medical centers, unless otherwise noted.

In response to requests, input was received from 2 specialty societies and 3 academic medical centers, one of which provided 4 responses and one of which provided 3 responses, while this policy was under review in 2016. Clinical input was focused on the categorization of partially implantable bone-anchored devices relative to fully implantable devices. There was strong consensus that partially implantable devices are considered an evolution of earlier devices, and that direct trials comparing the 2 are not necessary.

PRACTICE GUIDELINES AND POSITION STATEMENTS

In 2016, the American Academy of Otolaryngology – Head and Neck Surgery updated its position statement on the use of implantable hearing devices. It states that the Academy “considers bone conduction hearing devices, including implantation of a percutaneous or transcutaneous device and use of a bone conduction oral appliance or bone conduction scalp device to be acceptable, and in many cases preferred, procedures in the treatment of conductive or mixed hearing loss and single-sided deafness when performed by a qualified otolaryngologist-head and neck surgeon.”

U.S. PREVENTIVE SERVICES TASK FORCE RECOMMENDATIONS

Not applicable.

ONGOING AND UNPUBLISHED CLINICAL TRIALS

Some currently unpublished trials that might influence this review are listed in Table 2.
## Table 2. Summary of Key Trials

<table>
<thead>
<tr>
<th>NCT No.</th>
<th>Trial Name</th>
<th>Planned Enrollment</th>
<th>Completion Date</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Ongoing</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>NCT02022085</td>
<td>Post-market Clinical Follow-up of a Magnetic Bone Conduction Implant (Cochlear Baha Attract System)</td>
<td>52</td>
<td>Mar 2017</td>
</tr>
<tr>
<td>NCT01858246</td>
<td>A Randomised Controlled Trial Comparing Bone Anchored Hearing Aid With Bonebridge</td>
<td>60</td>
<td>Dec 2017</td>
</tr>
<tr>
<td><strong>Unpublished</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>NCT01715948</td>
<td>Comparison of Baha and CROS Hearing Aid in Single-Sided Deafness</td>
<td>9</td>
<td>Oct 2013 (completed)</td>
</tr>
<tr>
<td>NCT01822119</td>
<td>Clinical Performance of a Transcutaneous Bone Conduction Hearing Solution (Baha® Attract System). A Multicentre, Open, Prospective Clinical Investigation. 3 Months Investigation With a 6 Months Follow-up</td>
<td>27</td>
<td>Feb 2014 (completed)</td>
</tr>
<tr>
<td>NCT01264510</td>
<td>The Evaluation of the Effectiveness of Bone-anchored Hearing Aids (Baha) in Patients With Conductive or Mixed Hearing Loss, or Unilateral Deafness</td>
<td>150</td>
<td>Aug 2015 (completed)</td>
</tr>
</tbody>
</table>

NCT: national clinical trial.

* Denotes industry-sponsored or cosponsored trial.

### Coding

The following codes for treatment and procedures applicable to this policy are included below for informational purposes. Inclusion or exclusion of a procedure, diagnosis or device code(s) does not constitute or imply member coverage or provider reimbursement. Please refer to the member's contract benefits in effect at the time of service to determine coverage or non-coverage of these services as it applies to an individual member.

**CPT/HCPCS**

- 69710 Implantation or replacement of electromagnetic bone conduction hearing device in temporal bone
- 69711 Removal or repair of electromagnetic bone conduction hearing device in temporal bone
- 69714 Implantation, osseointegrated implant, temporal bone, with percutaneous attachment to external speech processor/cochlear stimulator; without mastoidectomy
- 69715 Implantation, osseointegrated implant, temporal bone, with percutaneous attachment to external speech processor/cochlear stimulator; with mastoidectomy
- 69717 Replacement (including removal of existing device), osseointegrated implant, temporal bone, with percutaneous attachment to external speech processor/cochlear stimulator; without mastoidectomy
- 69718 Replacement (including removal of existing device), osseointegrated implant, temporal bone, with percutaneous attachment to external speech processor/cochlear stimulator; with mastoidectomy
- L8690 Auditory osseointegrated device, includes all internal and external components
- L8691 Auditory osseointegrated device, external sound processor, replacement
- L8693 Auditory osseointegrated device abutment, any length, replacement only

- The following CPT codes describe semi-implantable bone-conduction hearing aids: 69710*, 69711*, 69714**, 69715**.
  *The Audiant bone conductor is a type of electromagnetic bone-conduction hearing device. While this product is no longer actively marketed, patients with existing Audiant devices may require replacement, removal, or repair.
  **Describe the BAHA device.
There are HCPCS codes specific to this device: L8690, L8691, L8693.

ICD-9 Diagnoses
380.15 Infective otitis externa; chronic mycotic otitis externa
380.16 Infective otitis externa; other chronic infective otitis externa NOS
380.23 Other otitis externa; other chronic otitis externa NOS
380.52 Acquired stenosis of external ear canal; secondary to surgery
381.10 Chronic serous otitis media, simple or unspecified
381.19 Chronic serous otitis media; other
381.20 Chronic mucoid otitis media, simple or unspecified
381.29 Chronic mucoid otitis media; other
381.3 Nonsuppurative otitis media and Eustachian tube disorders; other and unspecified chronic non-suppurative otitis media
382.00 Acute suppurative otitis media; without spontaneous rupture of ear drum
382.01 Acute suppurative otitis media with spontaneous rupture of ear drum
382.02 Acute suppurative otitis media in diseases classified elsewhere
382.1 Chronic tubotympanic suppurative otitis media
382.2 Chronic atticoantral suppurative otitis media
382.3 Unspecified chronic suppurative otitis media
382.4 Unspecified suppurative otitis media
382.9 Unspecified otitis media
389.00 Conductive hearing loss; unspecified
389.01 Conductive hearing loss, external ear
389.02 Conductive hearing loss, tympanic membrane
389.03 Conductive hearing loss, middle ear
389.04 Conductive hearing loss, inner ear
389.05 Conductive hearing loss, unilateral
389.06 Conductive hearing loss, bilateral
389.08 Conductive hearing loss of combined types
744.03 Anomaly of middle ear, except ossicles

ICD-10 Diagnoses (Effective October 1, 2015)
H60.61 Unspecified chronic otitis externa, right ear
H60.62 Unspecified chronic otitis externa, left ear
H60.63 Unspecified chronic otitis externa, bilateral
H60.8x1 Other otitis externa, right ear
H60.8x2 Other otitis externa, left ear
H60.8x3 Other otitis externa, bilateral
H60.91 Unspecified otitis externa, right ear
H60.92 Unspecified otitis externa, left ear
H60.93 Unspecified otitis externa, bilateral
H61.391 Other acquired stenosis of right external ear canal
H61.392 Other acquired stenosis of left external ear canal
H61.393 Other acquired stenosis of external ear canal, bilateral
H62.8x1 Other disorders of right external ear in diseases classified elsewhere
H62.8x2 Other disorders of left external ear in diseases classified elsewhere
H62.8x3 Other disorders of external ear in diseases classified elsewhere, bilateral
H65.21 Chronic serous otitis media, right ear
H65.22 Chronic serous otitis media, left ear
<table>
<thead>
<tr>
<th>Code</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>H65.23</td>
<td>Chronic serous otitis media, bilateral</td>
</tr>
<tr>
<td>H65.31</td>
<td>Chronic mucoid otitis media, right ear</td>
</tr>
<tr>
<td>H65.32</td>
<td>Chronic mucoid otitis media, left ear</td>
</tr>
<tr>
<td>H65.33</td>
<td>Chronic mucoid otitis media, bilateral</td>
</tr>
<tr>
<td>H65.411</td>
<td>Chronic allergic otitis media, right ear</td>
</tr>
<tr>
<td>H65.412</td>
<td>Chronic allergic otitis media, left ear</td>
</tr>
<tr>
<td>H65.413</td>
<td>Chronic allergic otitis media, bilateral</td>
</tr>
<tr>
<td>H65.491</td>
<td>Other chronic nonsuppurative otitis media, right ear</td>
</tr>
<tr>
<td>H65.492</td>
<td>Other chronic nonsuppurative otitis media, left ear</td>
</tr>
<tr>
<td>H65.493</td>
<td>Other chronic nonsuppurative otitis media, bilateral</td>
</tr>
<tr>
<td>H66.001</td>
<td>Acute suppurative otitis media without spontaneous rupture of ear drum, right ear</td>
</tr>
<tr>
<td>H66.002</td>
<td>Acute suppurative otitis media without spontaneous rupture of ear drum, left ear</td>
</tr>
<tr>
<td>H66.003</td>
<td>Acute suppurative otitis media without spontaneous rupture of ear drum, bilateral</td>
</tr>
<tr>
<td>H66.004</td>
<td>Acute suppurative otitis media without spontaneous rupture of ear drum, recurrent, right ear</td>
</tr>
<tr>
<td>H66.005</td>
<td>Acute suppurative otitis media without spontaneous rupture of ear drum, recurrent, left ear</td>
</tr>
<tr>
<td>H66.006</td>
<td>Acute suppurative otitis media without spontaneous rupture of ear drum, recurrent, bilateral</td>
</tr>
<tr>
<td>H66.011</td>
<td>Acute suppurative otitis media with spontaneous rupture of ear drum, right ear</td>
</tr>
<tr>
<td>H66.012</td>
<td>Acute suppurative otitis media with spontaneous rupture of ear drum, left ear</td>
</tr>
<tr>
<td>H66.013</td>
<td>Acute suppurative otitis media with spontaneous rupture of ear drum, bilateral</td>
</tr>
<tr>
<td>H66.014</td>
<td>Acute suppurative otitis media with spontaneous rupture of ear drum, recurrent, right ear</td>
</tr>
<tr>
<td>H66.015</td>
<td>Acute suppurative otitis media with spontaneous rupture of ear drum, recurrent, left ear</td>
</tr>
<tr>
<td>H66.016</td>
<td>Acute suppurative otitis media with spontaneous rupture of ear drum, recurrent, bilateral</td>
</tr>
<tr>
<td>H66.11</td>
<td>Chronic tubotympanic suppurative otitis media, right ear</td>
</tr>
<tr>
<td>H66.12</td>
<td>Chronic tubotympanic suppurative otitis media, left ear</td>
</tr>
<tr>
<td>H66.13</td>
<td>Chronic tubotympanic suppurative otitis media, bilateral</td>
</tr>
<tr>
<td>H66.21</td>
<td>Chronic atticoantral suppurative otitis media, right ear</td>
</tr>
<tr>
<td>H66.22</td>
<td>Chronic atticoantral suppurative otitis media, left ear</td>
</tr>
<tr>
<td>H66.23</td>
<td>Chronic atticoantral suppurative otitis media, bilateral</td>
</tr>
<tr>
<td>H66.3x1</td>
<td>Other chronic suppurative otitis media, right ear</td>
</tr>
<tr>
<td>H66.3x2</td>
<td>Other chronic suppurative otitis media, left ear</td>
</tr>
<tr>
<td>H66.3x3</td>
<td>Other chronic suppurative otitis media, bilateral</td>
</tr>
<tr>
<td>H66.41</td>
<td>Suppurative otitis media, unspecified, right ear</td>
</tr>
<tr>
<td>H66.42</td>
<td>Suppurative otitis media, unspecified, left ear</td>
</tr>
<tr>
<td>H66.43</td>
<td>Suppurative otitis media, unspecified, bilateral</td>
</tr>
<tr>
<td>H66.91</td>
<td>Otitis media, unspecified. right ear</td>
</tr>
<tr>
<td>H66.92</td>
<td>Otitis media, unspecified, left ear</td>
</tr>
<tr>
<td>H66.93</td>
<td>Otitis media, unspecified, bilateral</td>
</tr>
<tr>
<td>H67.1</td>
<td>Otitis media in diseases classified elsewhere, right ear</td>
</tr>
<tr>
<td>H67.2</td>
<td>Otitis media in diseases classified elsewhere, left ear</td>
</tr>
<tr>
<td>H67.3</td>
<td>Otitis media in diseases classified elsewhere, bilateral</td>
</tr>
<tr>
<td>H90.0</td>
<td>Conductive hearing loss, bilateral</td>
</tr>
<tr>
<td>H90.11</td>
<td>Conductive hearing loss, unilateral, right ear, with unrestricted hearing on the contralateral side</td>
</tr>
</tbody>
</table>
H90.12 Conductive hearing loss, unilateral, left ear, with unrestricted hearing on the contralateral side
Q16.4 Other congenital malformations of middle ear

**REVISIONS**

<table>
<thead>
<tr>
<th>Date</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>08-15-2014</td>
<td>Revised Title from Bone-Anchored Hearing Aids (BAHA) to Implantable Bone-Conduction and Bone-Anchored Hearing Aids (BAHA).</td>
</tr>
<tr>
<td></td>
<td>Updated Description section</td>
</tr>
<tr>
<td></td>
<td>In Policy section:</td>
</tr>
<tr>
<td></td>
<td>▪ Replaced the following medical policy language with updated policy language:</td>
</tr>
<tr>
<td></td>
<td>&quot;A. Unilateral Conductive or mixed hearing Loss&quot;</td>
</tr>
<tr>
<td></td>
<td>These patients are unable, for various reasons, to wear a conventional hearing aid or undergo surgery to improve their hearing: Chronic otitic media (COM), Congenital malformations of the external/middle ear, other acquired malformations of the ear that preclude wearing of conventional hearing aids. The criteria as taken from the FDA 510(K) document (#992873) are:</td>
</tr>
<tr>
<td></td>
<td>1. Average bone conduction threshold better (less) than 45 dB (at 500, 1000, 2000, 3000 Hz) in the indicated ear.</td>
</tr>
<tr>
<td></td>
<td>2. Speech discrimination score greater than 60% in the indicated ear.</td>
</tr>
<tr>
<td></td>
<td>3. Age 5 years or older.</td>
</tr>
<tr>
<td></td>
<td>B. Bilateral Conductive Hearing Loss</td>
</tr>
<tr>
<td></td>
<td>These patients have both ears involved in a conductive and mixed hearing loss and are not able to be treated with reconstructive surgery or conventional hearing aids for the above reasons. The criteria for the FDA 510(K) document #K011438 are:</td>
</tr>
<tr>
<td></td>
<td>1. Moderate (40 dB) to severe (70 dB) conductive hearing loss that is symmetric. That there is less than 10dB difference in average bone conduction (at 500, 1000, 2000, 4000 Hz) or less than 15 dB difference in bone conduction at individual frequencies.</td>
</tr>
<tr>
<td></td>
<td>2. Patients with mixed hearing loss with an average bone conduction better (less) than 45 dB in either ear (at 500, 1000, 2000, 4000 Hz)</td>
</tr>
<tr>
<td></td>
<td>3. Age 5 years or older.</td>
</tr>
<tr>
<td></td>
<td>C. Unilateral Sensorineural Hearing Loss (Single Sided Deafness; SSD)</td>
</tr>
<tr>
<td></td>
<td>These are patients where the nerve deafness in the indicated ear is so great that a conventional hearing aid no longer is useful. Typically, these patients are adults after acoustic neuroma surgery or sudden deafness and children with an unexplained deafness in one ear or after trauma. The implant is designed to stimulate the opposite (good ear) by bone conduction through the bones of the skull, therefore; the audiometric criteria are for the good ear. The criteria for the FDA 510(K) document #K021837 are:</td>
</tr>
<tr>
<td></td>
<td>1. Severe (70 dB) to profound (90 dB) hearing loss on one side with poor speech discrimination and unable to use a conventional hearing aid in that ear.</td>
</tr>
<tr>
<td></td>
<td>2. Normal hearing in the good ear as defined by an air conduction threshold equal to or better (less) than 20 dB (at 500, 1000, 2000, 3000 Hz).</td>
</tr>
<tr>
<td></td>
<td>3. Age 5 years or older.&quot;</td>
</tr>
<tr>
<td></td>
<td>Added Rationale section</td>
</tr>
<tr>
<td></td>
<td>In Coding section:</td>
</tr>
<tr>
<td></td>
<td>▪ Updated nomenclature for CPT codes: 69710, 69711, 69714, 69715, 69717, 69718</td>
</tr>
<tr>
<td></td>
<td>▪ Added HCPCS Codes: L8690, L8691, L8693</td>
</tr>
<tr>
<td></td>
<td>▪ Added Coding information</td>
</tr>
<tr>
<td></td>
<td>▪ Added ICD-10 Diagnosis (Effective October 1, 2015)</td>
</tr>
<tr>
<td></td>
<td>Added Revision section to the policy.</td>
</tr>
<tr>
<td>03-31-2015</td>
<td>Updated Description section.</td>
</tr>
<tr>
<td></td>
<td>Updated Rationale section.</td>
</tr>
</tbody>
</table>
REFERENCES


OTHER REFERENCES
2. Blue Cross and Blue Shield of Kansas Otolaryngology Liaison Committee consent ballot 12-08-05.